To investigate whether radiation-induced pneumonitis in the mouse-irradiated lung could be prevented by recombinant adenovirus-mediated soluble transforming growth factor-beta (TGF-b) type II receptor gene therapy. Radiation fibrosis-prone mice (C57BL/6J) were randomly divided into four groups consisting of a (1) control group (sham-irradiated); (2) radiation (RT)-alone group; (3) RT þ AdCMVsTbR group and (4) RT þ AdCMVluc group. The RT-alone and sham-irradiated mice were killed at several time points after thoracic irradiation with a single dose of 9 Gy, and then the TGF-b1 concentrations in serum and broncho-alveolar lavage fluid (BALF) were quantified by enzyme-linked immunosorbent assay (ELISA). We used an adenoviral vector expressing a soluble TGF-b type II receptor (AdCMVsTbR), which can bind to TGF-b and then block the TGF-b receptor-mediated signal transduction. The C57BL/6J mice were intraperitoneally (i.p.) injected with either 5 Â 10 8 plaque-forming units of AdCMVsTbR or AdCMVluc, a control adenovirus-expressing luciferase, a week preceding and a week following the X-ray thoracic irradiation. Four weeks after irradiation, the mice were killed and the concentration of TGF-b1 in the serum and BALF were then measured using ELISA and the lung tissue specimens were examined histopathologically. Following thoracic irradiation with a single dose of 9 Gy, radiation-induced TGF-b1 release in the serum reached the first peak concentration at 12 h and then declined. It reached a maximal value at 2 weeks after irradiation. In the BALF, the TGF-b1 concentration was appreciable within the first hour and thereafter declined. It reached a maximal value at 3 days after irradiation. A one-time i.p. injection of AdCMVsTbR 1 week before irradiation could not completely suppress the two peaks of the radiation-induced TGF-b1 increase, whereas an injection a week preceding and a week following thoracic irradiation was able to suppress those two peaks thoroughly. The TGF-b1 was completely suppressed in the AdCMVsTbR-treated mouse serum and BALF; however, no statistical difference was observed in the serum and BALF between the AdCMVluc-infected mice and the control mice at 4 weeks after irradiation (Po0.05). A histopathological examination showed only mild radiation pneumonitis in the irradiated lungs of AdCMVsTbR-treated mice in comparison to the AdCMVluc-infected and RT-alone mice. Our results demonstrated that TGF-b1 plays an important role in radiation pneumonitis, thus suggesting that the adenovirus-mediated overexpression in soluble TGF-b type II receptor gene therapy may be a potentially feasible and effective strategy for the prevention of radiation pneumonitis.
Introduction
Radiotherapy is an important conventional therapeutic modality in the treatment of malignant thoracic diseases, such as lung cancer, breast cancer, malignant lymphoma, esophageal cancer and thymoma. However, radiationinduced injury to the normal lung tissue, including radiation-induced pneumonitis and lung fibrosis, is inevitable and sometimes severe and even lethal. As a result, this kind of injury remains the main dose-limiting factor. [1] [2] [3] The clinical incidence of radiation-induced pneumonitis ranges from 5 to 10%, [4] [5] [6] and may be as high as 20%. 7 Although the definite molecular mechanism of such radiation-induced lung injury has not yet been elucidated, it is widely accepted that the process is initiated and sustained by multicellular interactions mediated by the cascade of activation of various cytokines, in which transforming growth factor-beta (TGF-b) plays a pivotal role. 8, 9 TGF-b, which has three distinct isoforms called b1-b3, is a multifunctional cytokine that elicits many cellular responses including the regulation of cell proliferation and differentiation and extracellular matrix production. [10] [11] [12] It also modulates apoptosis, angiogenesis, immunoregulation and wound healing. [13] [14] [15] [16] TGF-b is secreted as a latent precursor and is activated at the injury sites by mechanisms that are still not clearly understood but may include extremes of pH or proteolysis by plasmin, and reactive oxygen species produced by radiolytic hydrolysis and hypoxia. [17] [18] [19] The locally activated TGF-b is a potent chemoattractant for monocytes, macrophages and fibroblasts, and it stimulates their secretion of the inflammatory and fibrogenic cytokines, including TGF-b itself. 20, 21 Through these paracrine and autocrine mechanisms, activated TGF-b can maintain a high level at the injury sites.
Three major types of TGF-b receptors, type I, type II and type III, have been identified in most of the cells. 22 Type III receptor can enhance TGF-b binding to signaling receptors and restore the autocrine TGF-b activity in different model systems, yet it does not seem to directly transduce the TGF-b signal. 23 Both type I and type II receptors are transmembrane serine/threonine kinase indispensable for TGF-b signaling. The TGF-b binding to the extracellular domain of type II receptor is the first step in the activation of the signal transduction pathway, and it thereafter recruits type I receptor to form the heteromeric complexes. 24 Next, the type II receptor transphosphorylates the type I receptor and activates its kinase, and then initiates downstream signaling through the Smad-dependent or Smad-independent pathway. 25, 26 Therefore, type II receptor appears to play an essential role in the biological activity of TGF-b in vivo. [27] [28] [29] Some researchers have demonstrated, both in preclinical and clinical studies, a close relationship between the level of TGF-b and the radiation-induced pneumonitis. [30] [31] [32] [33] Furthermore, the use of soluble TGF-b type II receptor protein has been demonstrated to reduce bleomycin-induced lung fibrosis in hamsters and to ameliorate radiation enteropathy in mice. 34, 35 It is therefore logical to hypothesize that the intervention of TGF-b and its receptor may be a promising prophylactic target to prevent radiation-induced pneumonitis.
In this study, we constructed a replication-defective recombinant adenovirus carrying soluble TGF-b type II receptor cDNA, which can infect the cells and produce a soluble form of TGF-b type II receptor in the transfeted cells. This soluble receptor can bind TGF-b in a dominant-negative fashion, and then consequently block the TGF-b function. Using a similar vector, we demonstrated that it could also ameliorate renal fibrosis. 36 We herein detected the changes in the TGF-b1 level in the serum and broncho-alveolar lavage fluid (BALF) after thoracic irradiation, and investigated whether the radiation-induced pneumonitis could be prevented by the administration of this type of adenoviral vector.
Materials and methods

Preparation of adenoviral vectors
The recombinant adenoviral vector AdCMVsTbR, encoding the sequence of the type II TGF-b receptor extracellular domain fused to the human immunoglobulin Fc fragment under the control of cytomegalovirus (CMV) enhancer/promoter, was constructed using the 'AdEasy' method as previously reported. 37 The vector including the sequence of this fusion protein was kindly donated by Dr Yasuo Adachi (Osaka University, Osaka, Japan). The soluble TGF-b receptor expression cassette is integrated into the adenovirus genome in forward direction downstream from the left inverted terminal repeat. The soluble TGF-b receptor contains the first 159 amino acids of the human TGF-b type II receptor ectodomain, including the critical TGF-b-binding domain. Fusing the Fc fragment, including the hinge region, to the receptor ectodomain is expected to result in a dimerized soluble receptor 38 that is secreted into the circulation and can efficiently block downstream signaling. 39 This soluble receptor is secreted from AdCMVsTbR-infected cells, binds to TGF-b and inhibits TGF-b signaling. [40] [41] [42] An E1 À and E3 À adenoviral vector expressing the luciferase gene (AdCMVluc) driven by the CMV enhancer-promoter was constructed and used as a control virus. The titer of both virus solutions was assessed by a plaque formation assay using 293 cells, and then was expressed in plaque-forming units (PFU). All experiments were conducted in accordance with the institutional guidelines for Kyushu University.
Cell culture A549 cells (human lung adenocarcinoma cell), WI-38 cells (human fibroblast cell) and 293 cells (human embryonal kidney cell) were cultured in RPMI1640, minimal essential medium (MEM) and Dulbecco's modified Eagle's medium/F12, respectively, in a humidified incubator with 5% CO 2 at 371C. All the mediums were supplemented with 10% fetal bovine serum (FBS) (JRH Bioscience Inc., KS) and 1% penicillin-streptomycin (Invitrogen Corporation, Carlsbad, CA, USA). In vitro gene transfer into cells was carried out by incubation with the adenoviral vector in medium with 2% FBS and 1% penicillin-streptomycin in a humidified incubator with 5% CO 2 at 371C for 3 h with gentle agitation once per hour. After 3 h, the infection media was replaced with complete medium.
Measurement of sTbIIR in culture medium 1 Â 10 6 A549 cells were seeded into 24-well plates and incubated overnight, and then infected by AdCMVsTbR at multiplicity of infection (MOI) 0, 0.1, 1 and 10. After 3 days, the supernatant was collected and the amount of sTbIIR, which was tagged with the Fc portion of human IgG, was measured by enzyme-linked immunosorbent assay (ELISA) using an antihuman IgG antibody, as described previously. 39 Mesurement of secreted fibronectin induced by TGF-b A549 cells infected at MOI 1 with either AdCMVsTbR or AdCMVluc or left uninfected were incubated in RPMI1640 for 72 h. The medium was then collected, and the cell debris was removed by centrifugation (500 g, 10 min). Confluent WI-38 cells (1 Â 10 6 cells/well) were incubated in 24-well plate with a serum-free MEM for 24 h. The medium was then exchanged for a mixture of 200 ml supernatant prepared from A549 cells and 1.8 ml complete MEM medium. Recombinant human TGF-b1 (Wako pure chemical industry, Osaka, Japan) was supplemented to the mixture medium at a final concentration of 3 ng/ml. Human IgG (1.5 mg/ml) was added into the supernatant prepared from uninfected A549 cells to exclude any specific effect by the IgG Fc portion tagged to the soluble receptor. The WI-38 cells were incubated for another 24 h and then the supernatant was collected. After centrifugation, the concentration of fibronectin of the supernatant was determined using a fibronectin competitive ELISA kit (Angiopharm, O'Fallon, MO) according to the manufacturer's protocol.
Measurement of sTbIIR protein in mouse serum
Mice either given a single intraperitoneal (i.p.) injection of AdCMVsTbR (1Â 10 7 PFU) or AdCMVluc (1 Â 10 7 PFU) or those left uninfected were killed at 3 days after injection to confirm the existence of recombinant protein in the serum. Mice given a single i.p. injection of AdCMVsTbR (1 Â 10 7 PFU) were killed at 1, 3, 7 and 14 days after the injection to observe the changes of concentration of this recombinant protein in the serum. The amount of soluble TGF-b receptor tagged with the Fc portion of human IgG in the serum of C57BL/6J mice was measured by ELISA using an antihuman IgG antibody, as described above.
Animals
Female C57BL/6J mice, 8 weeks old and weighting approximately 20 g were used. The experiment was carried out under both the Guidelines for Animal Experiments of Kyushu University and the Law (No. 105) and Notification (No. 6) of the Japanese government. The mice were housed four to six per cage and kept under standard laboratory conditions, during which food and water were supplied ad libitum. Then, mice were allowed to acclimate themselves to the new environment after shipping for 1 week before treatment. Next, the mice were randomly distributed into four groups: (1) control (sham-irradiated); (2) radiation (RT)-alone; (3) RT þ AdCMVsTbR and (4) RT þ AdCMVluc.
Radiation schedule
The whole lung of each mouse was irradiated using 200 kVp X-rays with a single dose of 9 Gy at a dose rate of 0.9 Gy/min. The head, abdomen and extremities were shielded with lead strips. All the mice were anesthetized before irradiation with an i.p. injection of pentobarbital (40 mg/kg). The mice in groups 3 and 4 were injected in their peritoneal cavity with AdCMVsTbR and AdCMVluc, respectively, 1 week before and after irradiation.
Measurement of TGF-b1 concentration in the mouse serum and BALF after irradiation The serum and BALF samples of RT-alone mice were collected at time points of 1, 3, 6, 12, 24 and 72 h, and 1, 2, 3 and 4 weeks after thoracic irradiation. The serum and BALF samples of RT þ AdCMVsTbR and RT þ AdCMVluc and RT-alone mice were collected 4 weeks after irradiation. The concentration of TGF-b1 was measured using the TGF-b1 ELISA kit (R&D Systems Europe Ltd, Abingdon, UK) according to the manufacturer's protocol.
Histopathological examination
For the histological examination, the whole lung was fixed in 10% phosphate buffered formalin, paraffinembedded and sectioned at an average thickness of 3 mm with a microtome. The mounted sections were stained with hematoxylin and eosin. Lung damage was scored at five different areas. The extent of radiation-induced lung injury was graded by two observers (JU and KT) blinded to the treatment group, on a scale of 0 (normal lung) to 8 (total fibrous obliteration of the field) as described previously. 43 
Statistical analysis
The two-tailed Student's t-test was used to examine the significance of any difference between two groups with a single independent variable. A P-value o0.05 was considered statistically significant. All data are presented as the mean7standard error of the mean.
Results
Soluble receptor was produced from the AdCMVsTbRinfected A549 cells and this receptor suppressed the TGF-b1-induced fibronectin production in vitro We first examined whether the soluble receptors could be produced by AdCMVsTbR-infected A549 cells. After infection at different MOIs, we measured the level of soluble receptors in the medium by ELISA using an antihuman IgG antibody, and we confirmed this soluble receptor to be secreted into the AdCMVsTbR-infected A549 cell culture medium (data not shown). Next, we examined whether this soluble receptor could suppress the TGF-b1 function in vitro by the measurement of fibronectin induced by TGF-b1. 44, 45 TGF-b1-induced fibronectin synthesis in WI-38 cells, which was measured by competitive ELISA, was significantly suppressed when adding the medium prepared from the AdCMVsTbRinfected A549 cells. However, no such suppression on TGF-b1-induced fibronectin synthesis was observed when WI-38 cells were treated with the medium prepared from Expression of soluble TGF-b receptor in the mouse serum We next confirmed that the sTbIIR was produced in the mouse circulating blood after i.p. injection (Figure 2) . After an i.p. injection of AdCMVsTbR, we quantified the soluble receptor in the circulating blood using ELISA. A considerable amount of the sTbIIR was detected in the blood (Figure 3) . The serum level of the soluble receptor peaked on day 7 and thereafter declined gradually. However, it was still detectable on day 14.
An increased TGF-b1 concentration was detected in the serum and bronchiolo-alveolar lavage fluid after thoracic irradiation The results of TGF-b1 concentration in the serum and BALF in the RT-alone group after thoracic irradiation with 9 Gy and in the control group, respectively, were shown in Figure 4a and b. Following thoracic irradiation, the radiation-induced TGF-b1 increase in serum was already noticeable within 1 h and it reached a first peak after 12 h; subsequently, the TGF-b1 concentration declined gradually. However, the maximal level of serum concentration was evident 2 weeks after irradiation. The radiation-induced TGF-b1 in BALF reached the high level within 1 h, so far examined, then gradually declined. The maximal level of BALF was observed 7 days after irradiation.
After the i.p. injection of AdCMVsTbR, the sTbIIR in the circulating blood was found to inhibit the radiation-induced TGF-b1 increase We investigated whether the sTbIIR produced from the AdCMVsTbR-infected cells after an i.p. injection of AdCMVsTbR could inhibit the radiation-induced TGF-b1 increase. We found that the one-time injection of AdCMVsTbR (5 Â 10 8 PFU) 1 week before thoracic irradiation could inhibit the first peak of radiationinduced TGF-b1 increase (Figure 5a ). However, it could not inhibit the second peak completely. Therefore, we injected the AdCMVsTbR (5 Â 10 8 PFU) 1 week preceding and 1 week following thoracic irradiation, and found this administration modality was able to suppress these two peaks of radiation-induced TGF-b1 increase Figure 1 Inhibition of TGF-b1-induced fibronectin production by the soluble receptor in WI-38 cells. The medium was obtained from cultures of A549 cells that had been infected with AdCMVsTbR, AdCMVluc or left uninfected. Confluent WI-38 cells were stimulated with human TGF-b1 (3 ng/ml) in the above-mentioned medium. Human IgG (1.5 mg/ml) was added to the medium prepared from uninfected A549 cells. After 24 h culture, fibronectin was measured using competitive ELISA, and the means7s. Prevention of radiation-induced pneumonitis Z Haiping et al completely (Figure 5b) . Then, we examined the TGF-b1 concentration in the serum and BALF 4 weeks after thoracic irradiation in the RT-alone, RT þ AdCMVluc and RT þ AdCMVsTbR groups, respectively. We found the TGF-b1 concentration was significantly lower in the RT þ AdCMVsTbR group than in the RT-alone and RT þ AdCMVluc groups (Po0.05, Figure 6 ).
Histopathological analysis
The lung was resected 4 weeks after irradiation to analyze the lung damage histopathologically. Light microscopy of the lung sections of the RT-alone group and RT þ AdCMVluc group showed severe radiation pneumonitis, including interalveolar septa thickening, edema and an infiltration of inflammatory cells into the interstitium and the residual alveolar spaces as shown in Figure 7a . In contrast, the RT þ AdCMVsTbR group showed only mild to moderate thickening of the alveolar walls and minimal interstitial edema, and both inflammatory cells and a few focal areas of mild alveolitis were also evident. In contrast, the sham-irradiated group showed no noticeable changes. The lung damage scores showed no statistical difference between the RT-alone group and RT þ AdCMV-luc group (5.471.1 vs 4.870.8, P ¼ 0.374). However, both group scores were higher than those of the RT þ AdCMVsTbR group, whose scores In contrast, the injection of AdCMVsTbR a week preceding and a week following thoracic irradiation was able to completely suppress the radiation-induced TGF-b1 increase in comparison to the two injections of AdCMVluci or the mock injections. The mean value of three individual mice are shown.
Prevention of radiation-induced pneumonitis
Z Haiping et al were 1.670.8, and a statistical analysis showed a significant difference between both groups and the RT þ AdCMVsTbR group (P ¼ 0.00038 and 0.00037, respectively) as shown in Figure 7b .
Discussion
It is well known that irradiation of the lungs results in an increased expression of TGF-b, which has been reported to be related to the development of radiation-induced pneumonitis and fibrosis. [46] [47] [48] [49] An increased level of serum TGF-b has been associated with an increased risk for the development of radiation-induced pneumonitis in patients undergoing thoracic radiation therapy. 30, 32, 33, 50, 51 It is therefore logical to hypothesize that blocking TGF-b binding to its receptor would prevent radiation-induced pneumonitis. Using soluble TGF-b type II receptor protein has been reported to reduce the bleomycininduced lung fibrosis in hamsters and to ameliorate radiation enteropathy in mice. 34, 35 However, these strategies all require the long-term administration of the recombinant protein.
In this study, in an attempt to block the TGF-b signal pathway, we transferred soluble type II receptor gene mediated by the adenoviral vector into mice. Three kinds of TGF-b receptors have been identified. Because the TGF-b binding to its type II receptor is the first step to initiate the signal transduction pathway, we used the soluble TGF-b type II receptor in our study. After thoracic irradiation, two peaks of radiation-induced TGF-b1 increase were shown in the serum and BALF of the RT-alone group. These results correlate with previously published observations. 46 However, the peaks occurred earlier in the BALF than in the serum. One possible explanation for the different timing is the immediate injury to the alveolar type II cells, as detected by electron microscopy, 52 and the injured cells release TGF-b1 into the alveolar cavity.
Adenoviral vectors are quickly cleared after systemic administration in mice. 53, 54 As shown in Figure 3 , the soluble receptor reached a maximal value in 1 week after i.p. injection, and thereafter decreased quickly. It was not surprising to find in our study that only a one-time administration of AdCMVsTbR could not completely inhibit two serum peaks of the radiation-induced TGF-b1 increase, although it could inhibit the first peak and did cause a greatly decreased second peak. We therefore applied the AdCMVsTbR a week preceding and a week following the radiation treatment and this application modality could completely suppress the two TGF-b1 peaks and thus inhibit the TGF-b1 function thoroughly. A histopathological examination also confirmed only mild radiation-induced pneumonitis in the lungs of the RT þ AdCMVsTbR group in comparison with the RT-alone group and RT þ AdCMVluci group. Rabbani et al. 55 first demonstrated the effectiveness of adenovirusmediated soluble TGF-b type II receptor gene therapy to reduce the active TGF-b1 expression and ameliorate radiation-induced acute lung injury after thoracic irradiation in a rat experimental model, and Nishioka et al. 56 supported these results in a later experiment with a longer follow-up period using the same animal model. Our data confirmed both results using different administration modalities of adenoviral vector in a different animal model. Moreover, we demonstrated the biphasic pattern of irradiation-induced TGF-b1 increase in the serum and BALF. The fibrotic process in the lung has been investigated in detail using a bleomycin-induced lung fibrosis model by Phan SH et al. 57, 58 They have reported that the cellular sources of TGF-b1 were bronchial epithelial cells and alveolar macrophages within 3 days of lung fibrosis process. After that, the dominant sources of TGF-b1 changed to fibroblasts and myofibroblasts, and the TGF-b1 production from these cells was peaked at day 14. Moreover, it has been shown that TGF-b1-induced differentiation from fibroblasts to myofibroblasts via Smads. Although the cellular sources of Figure 6 (a) The concentration of TGF-b1 in the serum 4 weeks after thoracic irradiation was measured using ELISA. The TGF-b1 concentration was significantly lower in the RT þ AdCMVsTbR group than in the RT-alone and the RT þ AdCMVLuc groups (Po0.05). The mean value from three individual mice are shown. (b) The concentration of TGF-b1 in the bronchiolo-alveolar lavage fluid 4 weeks after thoracic irradiation was measured using ELISA. The TGF-b1 concentration was significantly lower in the RT þ AdCMVsTbR group than in the RT-alone and RT þ AdCMVluc groups (Po0.05). The mean value from three individual mice are shown.
Prevention of radiation-induced pneumonitis Z Haiping et al TGF-b1 remain to be elucidated in this study, the time course of the serum TGF-b1 concentration with biphasic pattern suggests the similar fibrotic process observed in bleomycin-induced lung fibrosis model. Therefore, the suppression of the first peak of TGF-b1 as well as the second peak seems to be effective for reducing lung damage in radiation-induced fibrosis.
Adenoviral vector has become a useful tool for the management of various disorders in many fields, including the radiation oncology field. 59, 60 For the prevention of radiation-induced pneumonitis, adenoviral vectormediated gene therapy is considered to be superior. Firstly, the adenovirus itself does not induce severe diseases; secondly, it lacks the potential to cause insertional mutagenesis; lastly, the transferred soluble TGF-b type II receptor gene does not integrate into the host genome, thus the transferred gene disappears with the division of the infected cells. Therefore, the transferred gene does not inhibit the normal physiological function of TGF-b for a long period. However, in the context of future clinical application, possible adverse effects regarding the long-term inhibition of the TGF-b function, such as carcinogenesis, should be carefully examined and efforts should be made to minimize the adverse effects directly related to the use of the adenoviral vector and to also optimize the administration methods.
In summary, our study demonstrated that TGF-b plays a critical role in the pathogenesis of radiation-induced penumonitis. We confirmed that the interaction of TGF-b with its receptor is a promising prophylactic target. The adenovirus-mediated overexpression of a soluble TGF-b type II receptor shown in our experiments appears to be a potentially feasible and effective gene therapy for radiation-induced pneumonitis. The lung damage by irradiation was quantitated by the scoring method as reported. 42 The damage scale was ranging from 0 (normal) to 8 (total fibrous obliteration), and graded by two observers. The mean value from three individual mice are shown.
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